奥妥珠单抗联合苯达莫司汀对比苯达莫司汀治疗复发慢性淋巴细胞白血病的随机2期研究
这项随机2期研究纳入复发慢性淋巴细胞白血病患者,分别接受奥妥珠单抗(20 mg/kg)联合苯达莫司汀(70 mg/m2)或苯达莫司汀单药治疗。联合组总缓解率为69%,单药组为39%(P=0·025);中位无进展生存期联合组为15·9个月,单药组为10·2个月(P=0·0192)。联合组发热和中性粒细胞减少发生率更高,但严重(3/4级)感染发生率未升高。
要点
- 联合组总缓解率69% vs 单药组39%(P=0·025)。
- 联合组中位无进展生存期15·9个月 vs 单药组10·2个月(P=0·0192)。
- 联合组发热34% vs 12%、中性粒细胞减少59% vs 39%,严重感染13% vs 27%。
核心结论
- 在复发或难治性慢性淋巴细胞白血病患者中,奥妥珠单抗联合苯达莫司汀较苯达莫司汀单药显著提高缓解率并延长无进展生存期。
研究设计与样本
- 随机2期研究,患者接受奥妥珠单抗(20 mg/kg)联合苯达莫司汀或苯达莫司汀单药治疗。
- 奥妥珠单抗每周静脉输注,两个28天周期后每14天一次,共四个28天周期;苯达莫司汀70 mg/m2 每个周期第1、2天静脉给药,最多六个28天周期。
- 联合组32例,单药组33例。
主要发现
- 按国际慢性淋巴细胞白血病工作组标准,总缓解率联合组69% vs 单药组39%(P=0·025)。
- 中位无进展生存期联合组15·9个月 vs 单药组10·2个月(P=0·0192)。
- 发热发生率联合组34% vs 单药组12%,中性粒细胞减少发生率联合组59% vs 单药组39%。
- 严重(3/4级)感染发生率联合组13% vs 单药组27%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Otlertuzumab (TRU-016) is a humanized anti-CD37 protein therapeutic that triggers direct caspase-independent apoptosis of malignant B cells and induces antibody-dependent cell-mediated cytotoxicity. Patients with relapsed chronic lymphocytic leukaemia (CLL) received either otlertuzumab (20 mg/kg) weekly by IV infusion for two 28-day cycles then every 14 days for four 28-day cycles and IV bendamustine (70 mg/m2 ) on Days 1 and 2 of each cycle for up to six 28-day cycles or bendamustine alone. Thirty-two patients were treated with otlertuzumab and bendamustine and 33 with bendamustine alone. Overall response rate according to the International Workshop on Chronic Lymphocytic Leukaemia criteria was 69% in the otlertuzumab and bendamustine arm and 39% in the bendamustine alone arm (P = 0·025). Median progression-free survival (PFS) was 15·9 months in the otlertuzumab and bendamustine arm and 10·2 months in the bendamustine alone arm (P = 0·0192). There was a higher incidence of pyrexia (34% vs. 12%) and neutropenia (59% vs. 39%) with the combination but this did not result in a higher incidence of severe (grade 3/4) infections (13% vs. 27%). This combination significantly increased the response rate and prolonged the PFS over single agent bendamustine in patients with relapsed or refractory CLL.
引用
- Robak T, Hellmann A, Kloczko J, et al. Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia. Br J Haematol. 2016. PMID: 27977057. doi:10.1111/bjh.14464
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。